A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis

Journal of the American Academy of Dermatology

Volumn 68, Issue 5, 2013, Pages 765-773

  Pariser, Robert J ^a,b   Paul, Joan ^b   Hirano, Stefanie ^a   Torosky, Cyndi ^a,b   Smith, Molly ^a,b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Virginia Clinical Research Inc   (United States)

Author keywords

adalimumab; efficacy; safety; sarcoidosis; treatment; tumor necrosis factor

Indexed keywords

ADALIMUMAB; PLACEBO;

ADULT; ANXIETY; ARTICLE; BURNING SENSATION; CELLULITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEADACHE; HISTOPATHOLOGY; HOARSENESS; HUMAN; HUMAN TISSUE; INFECTION; INFLUENZA; INJECTION SITE REACTION; INJURY; INSOMNIA; INTERTRIGO; LABORATORY TEST; LIVER VEIN THROMBOSIS; LUNG DISEASE; LUNG FUNCTION; MALE; MENSTRUAL IRREGULARITY; MUSCULOSKELETAL DISEASE; NASAL EROSION; NOSE DISEASE; PARESTHESIA; PNEUMONIA; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SARCOIDOSIS; SIDE EFFECT; SKIN INJURY; SORE THROAT; SWELLING; THORAX PAIN; TOOTH DISEASE; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VISUAL DISORDER; WEIGHT GAIN;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOPSY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; QUALITY OF LIFE; SARCOIDOSIS; SKIN DISEASES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876418216     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2012.10.056     Document Type: Article

References (30)

1. E.S. Chen, and D.R. Moller Sarcoidosis-scientific progress and clinical challenges Nat Rev Rheumatol 7 2011 457 467
2. C.R. Heath, J. David, and S.C. Taylor Sarcoidosis: are there differences in your skin of color patients? J Am Acad Dermatol 66 2012 121.e1 121.e14
3. A. Haimovic, M. Sanchez, M.A. Judson, and S. Prystowsky Sarcoidosis: a comprehensive review and update for the dermatologist, part I: cutaneous disease J Am Acad Dermtol 66 2012 699 716
4. L.H. Koch, M.H. Mahoney, and R.J. Pariser Cutaneous sarcoidosis manifesting as extensive verrucous plaques Int J Dermatol 49 2010 1458 1459
5. Y. Hosoda, S. Sasagawa, and N. Yasuda Epidemiology of sarcoidosis: new frontiers to explore Curr Opin Pulm Med 8 2002 424 428
6. B.A. Rybicki, M. Major, J. Popovich Jr., M.J. Maliarik, and M.C. Iannuzzi Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization Am J Epidemiol 145 1997 234 241
7. J.M. Reich, and R.E. Johnson Incidence of clinically identified sarcoidosis in a northwest United States population Sarcoidosis Vasc Diffuse Lung Dis 13 1996 173 177
8. G. Hillerdal, E. Nou, K. Osterman, and B. Schmekel Sarcoidosis: epidemiology and prognosis: a 15-year European study Am Rev Respir Dis 130 1984 29 32
9. S. Nagai, T. Handa, Y. Ito, K. Ohta, M. Tamaya, and T. Izumi Outcome of sarcoidosis Clin Chest Med 29 2008 565 574
10. A. Haimovic, M. Sanchez, M.A. Judson, and S. Prystowsky Sarcoidosis: a comprehensive review and update for the dermatologist, part II: extracutaneous disease J Am Acad Dermtol 66 2012 719 728
11. C.B. Doherty, and T. Rosen Evidence-based therapy for cutaneous sarcoidosis Drugs 68 2008 1361 1383
12. R.P. Baughman, M.A. Judson, R. Ingledue, N.L. Craft, and E.E. Lower Efficacy of apremilast in chronic cutaneous sarcoidosis Arch Dermatol 148 2012 262 264
13. J.R. Maneiro, E. Salgado, J.J. Gomez-Reino, L. Carmona BIOBADASER Study Group Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish Registry of Biologics BIOBADASER and a systematic review Semin Arthritis Rheum 42 2012 89 103
14. R.P. Baughman, M. Drent, M. Kavuru, M.A. Judson, U. Costabel, and R. du Bois Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement Am J Respir Crit Care Med 174 2006 795 802
15. R.P. Baughman, E.E. Lower, D.A. Bradley, L.A. Raymond, and A. Kaufman Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial Chest 128 2005 1062-47
16. M.D. Rossman, L.S. Newman, R.P. Baughman, A. Teirstein, S.E. Weinberger, and W. Miller Jr. A double-blind, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis Sarcoidosis Vasc Diffuse Lung Dis 23 2006 201 208
17. M.A. Judson, R.P. Baughman, U. Costabel, S. Flavin, K.H. Lo, and M.S. Kavuru Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomized trial Eur Respir J 31 2008 1189 1196
18. E. Stagaki, W.K. Mountford, D.T. Lackland, and M.A. Judson The treatment of lupus pernio: results of 116 treatment courses in 54 patients Chest 135 2009 468 476
19. Vigne C, Tebib J, Pacheco Y, Coury F. Sarcoidosis: an underestimated and potentially severe side effect of anti-TNF-alpha therapy. Joint Bone Spine doi: http://dx.doi.org/10.1016/j.jbspin.2012.05.001. Published online August 10, 2012.
20. Humira [package insert] 2012 Abbott Laboratories Abbott Park, IL
21. B. Scallon, A. Cai, N. Solowski, A. Rosenberg, X.Y. Song, and D. Shealy Binding and functional comparisons of two types of tumor necrosis factor antagonists J Pharmacol Exp Ther 301 2002 418 426
22. R.P. Baughman, S.A. Strohofer, J. Buchsbaum, and E.E. Lower Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis J Lab Clin Med 115 1990 36 42
23. M.W. Ziegenhagen, U.K. Benner, G. Zissel, P. Zabel, M. Schlaak, and J. Muller-Quernheim Sarcoidosis: TNF-α release from alveolar macrophages and serum level of sIL-2R are prognostic markers Am J Respir Crit Care Med 156 1997 1586 1592
24. A.Y. Finlay, and G.K. Khan Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use Clin Exp Dermatol 19 1994 210 216
25. C.E. Cox, J.F. Donohue, C.D. Brown, Y.P. Kataria, and M.A. Judson The sarcoidosis health questionnaire: a new measure of health-related quality of life Am J Respir Crit Care Med 168 2003 323 329
26. US Food and Drug Administration: Safety: what is a serious adverse event? Available from: URL: http://www.fda.gov/safety/medwatch/howtoreport/ucm053087. htm. Accessed June 23, 2012.
27. A.M. Thielen, C. Barde, J.H. Saurat, and E. Faffitte Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists Dermatology 219 2009 59 62
28. N.J. Sweiss, E.S. Barnathan, K. Lo, M.A. Judson, and R. Baughman C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis Sarcoidosis Vasc Diffuse Lung Dis 27 2010 49 56
29. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis doi: http://dx.doi.org/10.1136/annrheumdis-2011-201244. Published online May 5, 2012.
30. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. Available from: URL: http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed September 22, 2012.